403 Block C DIB Building Al Qasimia Sharjah - United Arab Emirates
Tel: +971 6 5511158
Real Time PCR Kits
Labgenomics, Korea; represents a complete range of Molecular assays for Covid -19, STD, HPV, Hereditary Diseases, Prenatal Genetic Testing, and NGS services.
Research & Development laboratory was established at Hacettepe University Technopolis in early 2011. Specific Single Nucleotide Mutation (SNP) Analysis systems were developed to detect many SNP analyses such as Factor V Leiden (G1691A), Factor V Cambridge (G1091C), and Factor II Prothrombin (G20210A), MTHFR C677T, and MTHFR A1298C mutations. Multiplex PCR development to detect some diseases, FMF (Familial Mediterranean Fever), CF (Cystic Fibrosis), etc. are in marketing. The kit system we developed is very fast, easy, confirmative, and reproducible. Our products are user-friendly and “Ready-to-Use”. The total time for each test is not more than one hour in the Real-Time PCR equipment. It does not require any specific equipment, materials, or specialized technical skills. The system can be run on most Real-Time PCR equipment.
A1 Life Sciences Inc., in 2019, RTA Laboratories Inc. was established as a subsidiary of A1 Capital with the investment support of A1 Capital. It offers R&D facilities for research projects, cleanroom production facilities for finished products, and a worldwide marketing network for ready-to-sell products.
It proposes a new business model that provides a common platform for potential stakeholders working in the fields listed below and wishing to join the global Biotechnology ecosystem.
Diatech Pharmacogenetics is the Italian leader in the development, production, and commercialization of pharmacogenetics tests for cancer precision medicine.
Founded in 1996, Diatech Pharmacogenetics has sustained constant organic growth over the years and now owns more than 70% of the Italian molecular diagnostic market and it is rapidly growing worldwide; to date, more than 20.000 diagnostic tests have been performed using its solutions and every year Diatech Pharmacogenetics reinvests 20% of its revenues in R&D.
